This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

Menu

Close

AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesDisease AwarenessDisease AwarenessAspergillosisOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseINSPIRE To: Change the Course Season 2The global threat of carbapenemase-producing enterobacterales (CPE)CPE Epidemiology CPE Factsheet London AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

A global health crisis under the spotlight

Carbapenemase-producing Enterobacterales (CPE), are spreading globally and alarming fast. 1,2

With antibiotic resistance infiltrating every corner of the world, it is time that we all pay attention. 3

Here, you will find information on carbapenemases, their rising threat and their epidemiology, across both Europe and in the UK. 

By better understanding how the prodution of CPE impacts patient care and outcomes, we can strive to take control of their rising threat. Together. 


 

The threat of CPE

CPE are a subset of carbapenem-resistant enterobacterales (CRE), which are enterobacterales that test resistant to at least one of the carbapenem antibiotics or produce a carbapenemase. 4-5

Carbapenemases can include metallo-β-lactamases (MBLs), Klebsiella pneumoniae carbapenemase (KPC) and Oxacillinase-48-like carbapenemases (OXA-48-like). 1,6

Globally, there are five main carbapenemases of clinical relevance known as the "Big Five" 1,6

Can you name them all? 

Discover the "Big Five"Loading
The mortality rate associated with infections caused by CRE can reach approximately 40% 7*

There is an urgent need to tackle problematic carbapenemases and slow their spread in difficult to treat organisms, 1,2,8 with the ultimate aim of helping to prevent unnecessary morbidity and mortality.

Explore the epidemiology in your regionLoading

* Based on the all cause 28-day mortality of carbapennemase producing Klebsiella pneumonia strains found through a retrospective observational study (N=205).7


Are you under threat from carbapenemases? 

Explore the epidemiology and learn about their incidence and prevalence in your region

Explore CPE epidemiologyLoading

References : 

1. Henderson J, et al. Hosp Infect 2020;104:12-9
2. Nordmann P, et al. Emerg Infect Dis 2011; 17:1791-8
3. World Health Organisation 2020. Antibiotic Resistance available at https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistancehttps://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Published July 2020: accessed March 2024
4. Center for Disease Control and Prevention. CRE technical information. Available at: https://www.cdc.gov/hai/organisms/cre/technical-info.html#Definition, published November 2019; accessed March 2024
5. Centers for Disease Control and Prevention. Carbapenem-resistant Enterobacteriaceae (CRE). Available at: https://www.cdc.gov/hai/organisms/cre/index.html. Accessed March 2024
6. Bonin RA, et al. Front Med(Lausanne) 2021; 7:616490
7. Daikos GL, et al. Antimicrob Agents Chemother 2014; 58:2322-8
8. Bonomo RA, et al Clin Infect Dis 2018; 66:1290-7
PP-UNP-GBR-8408. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​